Drug intelligence / Profile preview

AMX-003

Development stage: Preclinical
Lead developer: Amyl Therapeutics
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

AMX-003 is a preclinical-stage monoclonal antibody being developed by Amyl Therapeutics as a pan-amyloid immunotherapy. It is designed to target and bind to the aggregated, pathogenic forms of both amyloid-beta (Aβ) and tau proteins, which are hallmark features of neurodegenerative pathology. By addressing multiple misfolded protein species simultaneously, AMX-003 aims to provide a more effective treatment for Alzheimer's disease and Alzheimer's disease associated with Down syndrome compared to therapies targeting a single protein.

Targets

Aβ (Amyloid-beta peptides and aggregates)MAPT (Microtubule-associated protein tau)

Beyond the preview

Go deeper on AMX-003.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AMX-003.

Explore the full profile